Mary Schramke was named acting chief executive officer for Lynx Therapeutics effective Dec. 15, the company said this week. She succeeds Kevin Corcoran who resigned as president, CEO, and director to pursue another business opportunity, the company said. Schramke previously was vice president of business development for Lynx, where she has worked since 2003.